Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
FGM-108 by FutureGen Biopharm Technology for Metastatic Pancreatic Cancer: Likelihood of Approval
FGM-108 is under clinical development by FutureGen Biopharm Technology and currently in Phase II for Metastatic Pancreatic Cancer. According to...